Peter A Fasching1,2, Paul Gass3, Lothar Häberle3,4, Bernhard Volz3, Alexander Hein3, Carolin C Hack3, Michael P Lux3, Sebastian M Jud3, Arndt Hartmann5, Matthias W Beckmann3, Dennis J Slamon6, Ramona Erber5. 1. Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Nuremberg, Germany. peter.fasching@uk-erlangen.de. 2. Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA. peter.fasching@uk-erlangen.de. 3. Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Nuremberg, Germany. 4. Biostatistics Unit, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Nuremberg, Germany. 5. Comprehensive Cancer Center Erlangen-EMN, Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Nuremberg, Germany. 6. Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA.
Abstract
PURPOSE: Several clinical trials have investigated the prognostic and predictive usefulness of molecular markers. With limited predictive value, molecular markers have mainly been used to identify prognostic subgroups in which the indication for chemotherapy is doubtful and the prognosis is favorable enough for chemotherapy to be avoided. However, limited information is available about which groups of patients may benefit from additional therapy. This study aimed to describe the prognostic effects of Ki-67 in several common subgroups of patients with early breast cancer. METHODS: This retrospective study analyzed a single-center cohort of 3140 patients with HER2-, hormone receptor-positive breast cancer. Five-year disease-free survival (DFS) rates were calculated for low (< 10%), intermediate (10-19%), and high (≥ 20%) Ki-67 expression levels, as assessed by immunohistochemistry, and for subgroups relative to age, body mass index, disease stage, tumor grade, and (neo-)adjuvant chemotherapy. It was also investigated whether Ki-67 had different effects on DFS in these subgroups. RESULTS: The 5-year DFS rates for patients with low, intermediate, and high levels of Ki-67 expression were 0.90, 0.89, and 0.77, respectively. Ki-67 was able to further differentiate patients with an intermediate prognosis into different prognostic groups relative to common clinical parameters. Patients with stage II breast cancer had 5-year DFS rates of 0.84, 0.88, and 0.79 for low, intermediate, and high levels of Ki-67 expression. Ki-67 had different prognostic effects in subgroups defined by age and tumor grade. CONCLUSIONS: Ki-67 may help identify patients in intermediate prognostic groups with an unfavorable prognosis who may benefit from further therapy.
PURPOSE: Several clinical trials have investigated the prognostic and predictive usefulness of molecular markers. With limited predictive value, molecular markers have mainly been used to identify prognostic subgroups in which the indication for chemotherapy is doubtful and the prognosis is favorable enough for chemotherapy to be avoided. However, limited information is available about which groups of patients may benefit from additional therapy. This study aimed to describe the prognostic effects of Ki-67 in several common subgroups of patients with early breast cancer. METHODS: This retrospective study analyzed a single-center cohort of 3140 patients with HER2-, hormone receptor-positive breast cancer. Five-year disease-free survival (DFS) rates were calculated for low (< 10%), intermediate (10-19%), and high (≥ 20%) Ki-67 expression levels, as assessed by immunohistochemistry, and for subgroups relative to age, body mass index, disease stage, tumor grade, and (neo-)adjuvant chemotherapy. It was also investigated whether Ki-67 had different effects on DFS in these subgroups. RESULTS: The 5-year DFS rates for patients with low, intermediate, and high levels of Ki-67 expression were 0.90, 0.89, and 0.77, respectively. Ki-67 was able to further differentiate patients with an intermediate prognosis into different prognostic groups relative to common clinical parameters. Patients with stage II breast cancer had 5-year DFS rates of 0.84, 0.88, and 0.79 for low, intermediate, and high levels of Ki-67 expression. Ki-67 had different prognostic effects in subgroups defined by age and tumor grade. CONCLUSIONS:Ki-67 may help identify patients in intermediate prognostic groups with an unfavorable prognosis who may benefit from further therapy.
Entities:
Keywords:
Breast cancer; Ki-67; Molecular marker; Prognosis; Proliferation
Authors: Soon Bo Choi; Jung Min Park; Jee Hyun Ahn; Jieon Go; Jeeye Kim; Hyung Seok Park; Seung Il Kim; Byeong-Woo Park; Seho Park Journal: Breast Cancer Res Treat Date: 2022-01-13 Impact factor: 4.872
Authors: Christoph Thomssen; Tanja N Fehm; Elmar Stickeler; Peter A Fasching; Wolfgang Janni; Cornelia Kolberg-Liedtke; Hans-Christian Kolberg; Diana Lüftner; Volkmar Müller; Florian Schütz; Erik Belleville; Simon Bader; Michael Untch; Manfred Welslau; Marc Thill; Andreas D Hartkopf; Hans Tesch; Nina Ditsch; Michael P Lux; Achim Wöckel; Bahriye Aktas; Andreas Schneeweiss; Rachel Würstlein Journal: Geburtshilfe Frauenheilkd Date: 2022-02-11 Impact factor: 2.915
Authors: Tanja N Fehm; Manfred Welslau; Volkmar Müller; Diana Lüftner; Florian Schütz; Peter A Fasching; Wolfgang Janni; Christoph Thomssen; Isabell Witzel; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Michael P Lux; Bahriye Aktas; Maggie Banys-Paluchowski; Andreas Schneeweiss; Cornelia Kolberg-Liedtke; Andreas D Hartkopf; Achim Wöckel; Hans-Christian Kolberg; Nadia Harbeck; Elmar Stickeler Journal: Geburtshilfe Frauenheilkd Date: 2022-09-13 Impact factor: 2.754